From PROTACs to Molecular Glues: Outsourcing Complex Modalities in Targeted Protein Degradation

August 14, 2025

The U.S. small molecule drug discovery outsourcing market, valued at USD 1.49 billion in 2024, is anticipated to expand at a CAGR of 9.48% from 2025 to 2034, with growth increasingly driven by segment-wise performance across service types, therapeutic areas, and technological platforms. Unlike biologics development, which relies on biological systems, small molecule discovery remains rooted in synthetic chemistry, high-throughput screening (HTS), and computational modeling—processes that are highly amenable to outsourcing due to their modular nature and scalability. The medicinal chemistry segment dominates the market, accounting for over 35% of total revenue, driven by the persistent need for lead optimization, analog synthesis, and route scouting. Demand is particularly strong in kinase inhibitors, GPCR-targeted compounds, and covalent inhibitors, where structural complexity and intellectual property landscape require deep expertise and iterative design cycles.

Preclinical development services, including in vitro ADME (absorption, distribution, metabolism, excretion) and toxicology testing, represent another high-growth segment, fueled by regulatory expectations for early safety profiling and the rising cost of late-stage attrition. Application-specific growth is evident in oncology, central nervous system (CNS) disorders, and autoimmune diseases, where target validation and phenotypic screening are increasingly outsourced to specialized CROs with disease-specific assay platforms. The integration of artificial intelligence (AI) and machine learning in virtual screening and de novo molecule design is enabling faster hit identification and reducing reliance on physical compound libraries, creating new opportunities for value chain optimization.

By end-user, biotechnology firms represent the largest client segment, driven by their asset-light business models and reliance on external partners to advance pipelines from discovery to IND-enabling studies. Large pharmaceutical companies, while maintaining internal discovery units, are increasingly adopting “hub-and-spoke” models that centralize strategy in-house while outsourcing execution to low-cost, high-efficiency CROs. This shift reflects a broader trend of value chain optimization, as sponsors seek to reduce fixed R&D overhead and improve capital allocation efficiency. Segment-specific pricing varies significantly, with full-service discovery programs commanding multi-million-dollar contracts, while discrete services such as hit-to-lead optimization or metabolite identification are priced on a fee-for-service or FTE (full-time equivalent) basis.

Product differentiation is emerging through proprietary technologies, such as DNA-encoded libraries (DEL), fragment-based screening, and cryo-EM-enabled structure-based design. CROs like WuXi AppTec and Charles River have invested heavily in these platforms, enabling clients to explore novel chemical space and improve success rates. Additionally, the integration of digital lab notebooks, electronic data capture, and cloud-based collaboration tools is enhancing transparency and accelerating decision-making across distributed teams. As the industry moves toward more complex modalities—such as molecular glues, PROTACs, and covalent inhibitors—the ability to offer integrated, end-to-end discovery solutions with deep domain expertise will be a key differentiator in a competitive and consolidating market.

Competitive Landscape: